{
  "image_filename": "figure_p3_mrg_det_2_000.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/figure_p3_mrg_det_2_000.png",
  "image_type": "Figure",
  "page_number": 3,
  "block_id": "mrg_det_2_000",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "Diagram showing Kaiser Permanente Northern California service area facilities of various sizes grouped into two blocks (A and B) by similar size, with a table listing nine facilities and indicating their weekly alternating assignment between standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4) and quadrivalent recombinant influenza vaccine (RIV4) over four weeks. does not support the claim because the figure only depicts the cluster randomization and vaccine assignment schedule without providing any data on immune response breadth, cross-protection, or mismatch season performance Note: The image presents only study design and vaccine allocation; no immunologic or efficacy outcomes are shown.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Diagram showing Kaiser Permanente Northern California service area facilities of various sizes grouped into two blocks (A and B) by similar size, with a table listing nine facilities and indicating their weekly alternating assignment between standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4) and quadrivalent recombinant influenza vaccine (RIV4) over four weeks.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the figure only depicts the cluster randomization and vaccine assignment schedule without providing any data on immune response breadth, cross-protection, or mismatch season performance",
    "confidence_notes": "The image presents only study design and vaccine allocation; no immunologic or efficacy outcomes are shown."
  }
}